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An alarming increase in emergence of antibiotic resistance among pathogens worldwide has become a serious
threat to our ability to treat infectious diseases according to the World Health Organization. Extensive use of
antibiotics by livestock producers promotes the spread of new resistant strains, some of zoonotic concern, which
increases food-borne illness in humans and causes significant economic burden on healthcare systems. Furthermore,
consumer preferences for meat/poultry/fish produced without the use of antibiotics shape today’s market demand. So,
it is viewed as inevitable by the One Health Initiative that humans need to reduce the use of antibiotics and turn to
alternative, improved means to control disease: vaccination and prophylactics. Besides the intense research focused on
novel therapeutic molecules, both these strategies rely heavily on the availability of cost-effective, efficient and scalable
production platforms which will allow large-volume manufacturing for vaccines, antibodies and other biopharmaceuticals.
Within this context, plant-based platforms for production of recombinant therapeutic proteins offer significant advantages
over conventional expression systems, including lack of animal pathogens, low production costs, fast turnaround
and response times and rapid, nearly-unlimited scalability. Also, because dried leaves and seeds can be stored at
room temperature for lengthy periods without loss of recombinant proteins, plant expression systems have the potential
to offer lucrative benefits from the development of edible vaccines and prophylactics, as these would not require “cold
chain” storage and transportation, and could be administered in mass volumes with minimal processing. Several
biotechnology companies currently have developed and adopted plant-based platforms for commercial production
of recombinant protein therapeutics. In this manuscript, we outline the challenges in the process of livestock
immunization as well as the current plant biotechnology developments aimed to address these challenges.Table of contents
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1. Introduction
The health and well-being of food-bearing animals is a
major preoccupation for any livestock, poultry or fish pro-
ducer. Endemic disease or epidemic outbreaks represent a
very significant financial risk to the producer due to loss
of animals, production of animals that are not marketable,
and reduction in feed conversion efficiency. The potential
risk to consumers from contaminated food is an import-
ant public health concern, and very significant investments
are made by the agri-food industry to ensure safe food
products. Nevertheless, an estimated 9.4 million cases of
illness due to consumption of food contaminated with
known pathogens occurs annually in the United States [1].
Thus, it is critically important that primary producers en-
sure the health of their livestock for public health, animal
welfare and business profitability reasons.
The key to minimizing animal morbidity and mortality
is the employment of good production practices. Best
practices will vary according to the production system,
but land-based agriculture will typically include provision
of uncontaminated feed and water, adequate ventilation
and air quality, biosecurity, robust surveillance of animal
health, and the judicious use of antimicrobial agents and
parasiticides for disease prevention and treatment, when
warranted. Prominent in the animal health toolbox are
antibiotics. It can be reasonable to assume that the avail-
ability of antibiotics will become increasingly constrained
as legitimate public alarm over the looming spectre of
catastrophic antibiotic resistance in human medicine is
translated into action at the farm level. Furthermore, the
development of antibiotic resistance will progressively re-
duce antibiotic therapy options available to veterinarians.
More restricted use of veterinary antibiotics will result
from market-driven forces, as consumers increasingly
demand antibiotic-free food, and through the policies of
governments and codes of practice of veterinary practi-
tioners that promote judicious use [2]. Within this
evolving environment, newly developed vaccines and
immunotherapeutic agents offer the potential to lessen
the need for antibiotics for disease control, and offer
veterinary practitioners much needed tools [3].
The global market for animal vaccines is estimated to be
currently worth $5.8 billion, and is anticipated to grow
with a compound annual growth rate of 8.1% to a value of
$8.6 billion by 2018 [4]. The efficacy of a vaccine, the ease
with which it can be employed, and the overall benefit
in terms of increased productivity must be competitivewith other disease management options. Recent advances
in immunology and in biotechnology, specifically the
development of methods to produce potent vaccines very
cost-effectively using plant-based bioreactors have the po-
tential to make vaccines an even more attractive propos-
ition. Furthermore, in cases where vaccination cannot be
used to prevent disease, the production of antibodies in
plants for passive immunotherapy and infectious disease
control holds great promise.
This review paper will cover animal immunization es-
sentials and will present the latest developments in plant
biotechnology for the production of veterinary therapeu-
tics. Specific aspects discussed will include high-level re-
combinant protein production in plant-based systems,
the ability to use unpurified material for treatment, the
possibility of oral rather than parenteral delivery, low cost
of protein/vaccine production, very short turnaround time
from conception to large-scale manufacturing, and the
ability to “stack” genes encoding antigens and adjuvants to
create potent multi-target vaccines in a single preparation.
2. Immunization of livestock animals
2.1 Active/passive immunization
In contrast to humans, newborn farm animals (foals,
piglets, calves, lambs, kids) depend totally, and companion
animals (kittens, puppies) almost completely upon uptake
of colostral antibodies for their systemic maternal immunity
against pathogens [5]. Intestinal uptake occurs via endo-
cytosis, involving the neonatal Fc receptor (FcRn) and is
highest immediately after birth and declines rapidly within
24 h as intestinal cells mature and intestinal flora are estab-
lished. The time of cessation of this macromolecular trans-
port (gut closure) varies by species and immunoglobulin
type, ranging between 20 to 36 h of age [6]. For multipar-
ous animal species, the degree of passive immunity can be
heterogeneous between litters and among members of a
same litter because of variability in colostral absorption.
This is true for piglets, puppies and kittens, whose levels of
passive antibodies are maximum 36-48 h after birth. From
this time on, the immunoglobulin concentrations decline in
the serum of the newborn animal. The half-life depends on
immunoglobulin isotype, and on the species, varying be-
tween 1 to 4 days for IgA and IgM, to approximately 8 to
22 days for canine and equine IgG, respectively [7]. The af-
finity of IgG for endothelial FcRn most likely accounts for
these differences observed in serum half-life among species
and different IgG subclasses [7,8]. Also, the growth rate of
the animal influences the rate of decline in the level of the
maternally-derived antibodies. This is particularly clear in
canine species, where dogs belonging to rapid growth
breeds eliminate their maternally-derived antibodies more
quickly than slow-growth breeds. In addition to differences
in uptake of maternal antibodies, the degree of passive im-
munity is not equal for all tissues. For instance, colostral
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during the first months of life, whereas the respiratory tract
mucus is protected only for a few weeks [9].
Shortly after parturition, drastic changes occur in the
composition of colostrum with a drastic drop in IgG and
IgA. In most domestic animals, the drop in IgA is less
pronounced than IgG, so that IgA becomes the most im-
portant immunoglobulin in milk [10]. Milk antibodies are
essential to protect young animals against intestinal infec-
tions. The IgA in the milk is dimeric secretory IgA (SIgA).
The dimeric IgA is secreted in the mammary gland tissue
by plasma cells, binds with its J chain to the polymeric im-
munoglobulin receptor (pIgR) expressed at the basolateral
site of the alveolar epithelial cells and is endocytosed, trans-
cytosed and exocytosed to the interstitial space after cleav-
age of the receptor. The extracellular 80 kDa part of pIgR is
exceptionally carbohydrate-rich, and when incorporated
into the Ig molecules as bound secretory component (SC),
it endows SIgA with resistance against proteolytic degrad-
ation [11]. In ruminants, IgG concentrations remain higher
than IgA, and IgG1 is specifically enriched in colostrum
and milk, with levels approximately 10 times higher than
IgA or IgG2. The role of FcRn in this transport has not
been completely clarified [7,8].
2.2 Induction of protective immunity
At weaning, lactogenic protection disappears, making
the young animals highly susceptible to infections with
enteropathogens. Most pathogens either colonize the mu-
cosa or invade the host at a mucosal surface. Optimal pro-
tection against these pathogens most often involves the
induction of pathogen-specific SIgA at the infection site
[12]. As such, an optimal vaccine should induce robust
mucosal SIgA immune responses.
Parenteral vaccines typically induce IgG, a response that
is not particularly effective against these types of infections.
The best way to elicit pathogen-specific SIgA is to activate
the local mucosa-associated lymphoid tissue (MALT) at the
site of colonization or invasion through mucosal vaccin-
ation. This necessity to administer vaccines at the mucosal
site relating to the pathogen’s tropism is further highlighted
by the compartmentalization of the mucosal immune sys-
tem. For example, stimulation of gut-associated lymphoid
tissue (GALT) does not induce a protective SIgA response
in the respiratory tract, while induction of an immune re-
sponse at the nasal mucosa fails to induce intestinal protec-
tion [11,13]. Taking this into account, the induction of
mucosal immunity further requires the vaccine to pass sev-
eral physiological barriers and defence mechanisms. To
reach the inductive sites of the mucosal immune system,
whether it is upon oral, intranasal, rectal or urogenital ad-
ministration, the vaccine has to surmount mucus and anti-
microbial peptides and traverse the epithelial barrier. In
case of oral administration, the vaccine also needs tosurvive the low pH in the stomach, digestive enzymes and
bile salts and be transported via peristalsis to the GALT.
Furthermore, the vaccine has to trigger protective mucosal
immunity instead of tolerance, which is the dominant re-
sponse mode of the mucosal immune system, and this
without causing severe inflammation [13]. Fusing vaccine
antigens to antibody or antibody fragment to target the
subunit vaccine to antigen-sampling routes at the mucosal
surfaces, such as transcytotic epithelial receptors, could
drastically improve oral vaccine efficacy [14].
Only a limited number of mucosal vaccines have been
shown to meet these criteria and, consequently, only a few
have been internationally licensed. Of those that have been
licensed, most are based on live-attenuated pathogens and a
few are inactivated pathogens [15]. No mucosal subunit vac-
cines have been licensed so far. Whereas many particle sys-
tems, such as virus-like particles (VLPs, see text) or other
particles have been shown to be immunogenic in mice via
the oral route, almost none of these were successful in larger
animals or humans [3]. This could be explained by the lon-
ger intestinal transit time for these particles to reach the in-
ductive sites in larger mammalian species in contrast with
mice. As a result, in larger animals, only a small portion of
the particles will reach the GALT, resulting in fewer particles
being taken up by M cells and subsequently no or low in-
duction of intestinal mucosal immune responses.
In contrast to particulate systems, soluble antigens are
not immunogenic and in general induce tolerance upon
mucosal administration even in mice. However, a few
soluble antigens have been shown to be immunogenic via
the mucosal route, such as cholera toxin (CT), thermo-
labile enterotoxin (LT) and their B subunits (CTB and
LTB) [16], and the purified F4 fimbriae of enterotoxigenic
E. coli in pigs [17]. These antigens are characterized by
the ability to bind to receptors on enterocytes in the
small intestine and to be taken up by these epithelial cells
[18], followed by induction of an antigen-specific IgA
response. Whereas microgram quantities of CTB and
LTB are immunogenic, F4 has to be given in milligram
amounts [17]. The oral route has the advantage over
other routes in that the vaccine antigens can be adminis-
tered in the feed, eliminating the need to restrain
livestock during administration and allowing the use of
less-purified antigens.
2.3 Modes of vaccination
2.3.1 Subcutaneous and intramuscular
The delivery of veterinary vaccines, in general, is by in-
jection although there are variations depending upon the
animal species being immunized, management practices
and age of the animal. For example, virtually all vaccines
for cattle are delivered parenterally, while those for use
in poultry are delivered by injection, orally, or by aero-
sol. Ultimately, the route of delivery is dictated largely
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as the ease of handling of individual animals.
There are a number of issues associated with invasive
vaccine delivery in food-producing animals, one of which
is the economic loss associated with trimming of area sur-
rounding injection site lesions. Many veterinary vaccines
are extremely pro-inflammatory in nature, an example be-
ing Clostridial vaccines used in cattle. When delivered
subcutaneously, these vaccines tend to result in a large
swelling which can persist for months. On the other hand,
intramuscular injection does not result in overt swelling
but causes significant tissue damage near the injection site.
The cost associated with carcass trimming has been esti-
mated to be between $1.46 and $40.00 per animal [19]. In
addition, it is not uncommon for needles to break during
intramuscular delivery, causing problems at processing, as
well as the retail level. While injection of the antigens
themselves can result in tissue damage, most killed vac-
cines also contain strong adjuvants which contribute to
this damage. Adjuvants significantly increase the cost of
the vaccines and also dictate both the quality and magni-
tude of the immune response, the former of which has
been biased towards Th2 immune responses. Adjuvants
currently in use are suitable for injection, but most are not
compatible with mucosal delivery [20]. To maintain their
efficacy, most injectable vaccines require proper refriger-
ation and storage, a need that can be challenging in exten-
sive livestock operations especially in developing nations.
2.3.2 Intranasal
The delivery of modified live viral vaccines via the intra-
nasal route or in drinking water has been effective. How-
ever, live bacterial vaccines are not commonly used, in
part due to the use of antibiotics in the industry. Muco-
sal vaccines are available for swine, including those for
Bordetella bronchiseptica, where they have been shown
to result in enhanced SIgA production following a single
administration by the intranasal route [21]. A novel adju-
vant platform consisting of CpG ODNs, polyphospha-
zenes and cationic innate defense regulator peptide (IDR)
1002, has also been tested for efficacy in a swine model
and shown to provide a long duration of immunity against
Bordetella pertussis in mice following a single intranasal
administration [22]. Interestingly, this formulation also
works in the presence of maternal antibodies [23], making
it ideal for mucosal immunization of neonates.
All presently available commercial vaccines targeting
the respiratory tract via intranasal, aerosol or conjunctival
application are live attenuated or vector vaccines [24].
Nevertheless, there is the potential for using protein vac-
cines consisting of dead microorganisms or subunits (viru-
lence factors). Immunization of the respiratory tract has
been experimentally demonstrated by i) using particulate
delivery systems, which are either lipophilic, mucoadhesiveand/or contain immunomodulating molecules, ii) using sol-
uble conjugates of antigens (or epitopes) and a carrier, tar-
geting the antigens to the mucosa of the respiratory tract or
iii) using soluble antigens. Often, adjuvants are needed for
strong mucosal immune responses [25]. Whereas experi-
mental results have been promising in many studies, no
dead vaccines for immunization of the respiratory tract
have been commercialized, as adverse reactions have ham-
pered their development. Indeed, anaphylaxis due to im-
purities, or Bell’s palsy due to vaccine components have
been described [26]. Results from animal studies suggest
that the intranasal route may itself facilitate transport of
proteins, inactivated vaccines, live viruses or other particles
into the central nervous system [27]. Therefore, candidate
vaccines targeting the respiratory tract mucosa have to be
thoroughly evaluated for adverse effects.
2.3.3 Oral
Oral vaccination, or so called “edible vaccines”, have been
traditionally viewed as the panacea of plant-produced
vaccines in terms of their use as an approach to disease
control [28]. Edible vaccines offer several advantages over
conventional methods of vaccine delivery. Edible vaccines
come in contact with the lining of the digestive tract, thus
giving them the potential to stimulate both mucosal and
systemic immunity, the former of which is a response that
is notoriously difficult to achieve through injections, which
bypass mucosal barriers. In part, this accounts for the rea-
son as to why the efficacy of injectable vaccines against in-
testinal pathogens has generally been quite poor.
Edible vaccines also have positive implications for live-
stock welfare, as they could be administered directly in
the diet, eliminating the need to confine the animal, or
the need to breach the skin through injection, a practice
that can promote secondary infections. Oral administra-
tion of vaccines eliminates the risks that injection-based
methods pose on meat quality as a result of intramuscu-
lar administration.
3. Plant-based bioreactors
Being eukaryotic organisms, plants can express, synthesize
and process complex heterologous proteins similarly to
“conventional”, fermentation-based expression systems,
such as mammalian, insect and yeast cell cultures. Yet,
plants have some variances in the pattern of protein gly-
cosylation [29]. Production of recombinant therapeutic
proteins has been demonstrated in a variety of plant
species. Plant cells contain genomes of three types: nu-
clear, chloroplast (plastome) and mitochondrial genomes.
Generation of stable transgenic plants that produce re-
combinant proteins can be efficiently achieved through
genetic engineering of the nuclear genome or the plas-
tome. In addition, transient expression methods allow
quick and robust production of recombinant proteins by
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harboring agrobacteria [30].
Recombinant proteins produced in nuclear-transformed
plants are synthesized in the cytoplasm and can be se-
creted, or accumulated in different sub-cellular organelles
with the use of appropriate transit or signal peptides. Using
tissue-specific promoters enables spatially-defined expres-
sion of the transgene in applicable plant organs, such as
leaves, seeds, fruits or tubers [31]. Nuclear-transformed
plants offer tremendous simplicity for production of a
vaccine product, as seed lines can be developed and
propagation of plant biomass can utilize traditional agri-
cultural technologies and infrastructure. Note, however,
that nuclear-transformed plants typically express lower
yields of recombinant proteins compared with transient
expression, require prolonged timeframes for generation
and selection of transgenic seed lines, and require mea-
sures to prevent environmental contamination due to
transgene flow via open field cross-pollination [32].
Transgenic plants with transformed plastome (trans-
plastomic plants) possess several beneficial traits, such as
i) high-ploidy of plastome and lack of positional effects or
transgene silencing, leading to synthesis of typically very
high levels of recombinant proteins, ii) the ability to ex-
press artificial operons, thus allowing expression of several
proteins in one transformational step, and iii) tight trans-
gene containment due to maternal inheritance of plastid
DNA in most cultivated plants [33]. The absence of a gly-
cosylation machinery in chloroplasts thwarts the expres-
sion of proteins where glycans are essential for structure/
conformation; however, this technology eliminates risks of
addition of potentially allergenic non-mammalian glycans
and offers advantages for expression of non-glycosylated
proteins of prokaryotic origin [34].
High yields of recombinant proteins can be obtained
quickly with transient expression systems through use of
viral, virus-derived and non-viral expression vectors [30].
Infiltration of the leaf tissue with an Agrobacterium inter-
mediate host containing any of these types of expression
vectors (agroinfiltration) is the most common method used
for delivery of foreign DNA into plant cells. The main ad-
vantage of the transient expression systems is the produc-
tion speed that enables vaccines to be manufactured within
periods as short as one month after obtaining the sequence
of the antigen [35]. However, transient expression systems
are labor- and material-intensive procedures involving
growing Agrobacterium cultures, and diluting them in
infiltration cocktails, immersion of plant aerial biomass
into the Agrobacterium suspension, infiltrating the
agrobacteria into leaves by pulling and releasing a vac-
uum to allow entry of Agrobacterium into the plant tis-
sues [36]. These manipulations add cost to recombinant
protein production, but have the advantage of using wild
type plants, which is viewed by regulatory authoritiesfavorably. The US Defense Advanced Research Program
Agency (DARPA) has funded major infrastructure projects,
such as Medicago’s [37] commercial-scale production facil-
ity in the Research Triangle Park, NC, and Kentucky Bio-
Processing’s [38] production facility in Owensboro, KY.
Also, an improved viral vector-based inducible system that
can be deployed for field production has recently been de-
veloped [39].
Other plant-based production systems include algae
and moss cell-suspension cultures grown in bioreactors.
High-level containment and sterile growth conditions are
advantages of these systems, compared to whole plants in
terms of good manufacturing practice (GMP) for recom-
binant protein production, though the cost of these sys-
tems is high, while scale-up ability is limited [40].
4. Post-translational protein modifications in plants
Although the genetic code is universal and a given nu-
cleotide sequence results in the same order of amino
acids in the polypeptide regardless of what organism is
translating the RNA message, proteins differ in structure
depending on the organism they are produced in. This is
due to the fact that a multitude of modifications can
take place after the ribosomal synthesis of the polypep-
tide, so called post-translational modifications (PTMs).
In the case of therapeutic proteins these PTMs are of
high importance, since they might alter the structure of
the protein, its functionality and especially its immuno-
genicity [41]. PTMs include glycosylation, phosphoryl-
ation, lipidation, disulfide-bridging (to name only the most
prominent), which basically occur in vivo, but some might
also occur during downstream processing of a given thera-
peutic protein. Different organisms are capable of various
PTMs, e.g. bacteria do not glycosylate proteins, while
eukaryotic organisms perform extensive glycomodifica-
tions. Moreover, type and linkage of sugars vary consider-
ably among cell types and organs, as well as at different
developmental stages and environmental conditions, mak-
ing this particular modification highly diverse. In the case
of recombinant therapeutics for parenteral administration,
it is of importance to retain the native glycosylation pat-
tern to avoid shortened half-life and unintended immuno-
genicity. Plants do glycosylate recombinant proteins in a
manner that differs from that in mammalian cell systems,
and glycosylation may even vary among plant species, or-
gans and cell types. In some cases this can even be an ad-
vantage, exemplified by a recombinant glucocerebrosidase
(taliglucerase alfa) made in carrot cells. Here, the sugars
added to the produced recombinant enzyme more closely
resemble the native structure with terminal mannose,
making this product superior or “biobetter”, compared to
the CHO cells-derived product [42]. As a further improve-
ment, glycosylation machinery in plants can be engineered
to produce mammalian-like glycan patterns with terminal
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tinguishable from those produced in mammalian cell lines
(see “Glycoengineering” in text).
5. Opportunities and advantages of plant systems
5.1 Storage/Shelf life/Purification
Plant-based expression systems raise the possibility that
antigens or antibodies can be produced in a form that is
stable during storage and is amenable to extraction and
purification procedures [43]. Dried or lyophilized leafy
biomass, as well as plant storage tissues, such as seeds,
retain unchanged levels of accumulated recombinant
proteins for years at normal room temperatures, thus re-
ducing stowing costs and facilitating distribution without
need for a cold chain [44,45]. Such a production system
would allow stockpiling of the transgenic plant material
(lyophilized leaf biomass or seeds) for manufacturing of
rapid-response veterinary biologics targeted against patho-
gens of epidemiological relevance. The time to product
would then only be dependent on the speed of extraction
and downstream processing, if purification is required, or
immediate, if formulated lyophilized biomass or whole
seeds can be administered in feed [46]. Some plant-based
expression strategies, such as the expression of recombin-
ant antigens in oil bodies or implementation of particular
protein tags are specifically focused at overcoming the
complexities of purification procedures (reviewed in [47]).
Although purified plant-derived biologics are functional
and effective, a key benefit of plants is the ability to deliver
recombinant pharmaceuticals as minimally processed feed,
such as flour paste from edible tissues [48]. Expression in
seeds may also help protect antigens from digestion within
the intestinal tract, especially if they target the formation
of protein bodies, which can increase the delivery of anti-
gens to the mucosal surface [49]. Remarkably, the forma-
tion of ectopic storage organelles as sink compartments
for recombinant proteins can be induced in tissues that
are not adapted for storage functions [50].
5.2 Glycoengineering
Glycosylation affects the quality of recombinant pharma-
ceuticals as different glycan structures can potentially in-
fluence stability, subcellular targeting, immunogenicity,
pharmacokinetics and biological activity. The precise
control and optimization of glycan modification to
manufacture homogeneous protein therapeutics with
specific designer glycoforms that confer superior effi-
cacy has therefore become an important issue for all
production platforms, including mammalian cells.
The mechanisms of N-glycosylation in plants and mam-
mals differ in Golgi-specific modifications, such as the
addition of β(1,2)-linked xylose and core α(1,3)-linked
fucose residues in plants, and the addition of β(1,4)-
linked galactose and sialic acid residues in mammals[51]. Therefore, strategies to control the glycosylation of
recombinant proteins were established in plants early
on, such as subcellular targeting to prevent the addition
of certain sugar residues [52] and glycoengineering to
replace sugars with more desirable counterparts [53]. A
key example of glycan control by targeting is the first
commercially available plant-derived human therapeutic
protein, taliglucerase alfa, indicated for the lysosomal
storage disorder called Gaucher’s disease. In this case
targeting to the plant vacuole resulted in the formation
of glycan structures with terminal mannose residues pro-
moting uptake of the recombinant protein via mannose-
specific surface receptors on macrophages [54].
Engineering the plant N-glycosylation pathway has been
achieved by various approaches including conventional
mutagenesis or homologous recombination, RNA interfer-
ence and transgene expression [53]. The versatility of
plants for the production of specific N-glycoforms has
turned a perceived disadvantage into one of the major
strengths of plant production platforms. In addition to
the abolition of β(1,2)-linked xylose and core α(1,3)-
linked fucose residues, and the complete reconstruction
of mammalian glycosylation pathways in plants [55],
product-specific designer N-glycans have been engineered
for improved efficacy. For example, glycoengineered plants
can be used to produce glyco-optimized antibody versions
with improved pharmacokinetic properties due to greater
receptor affinity [56].
Another type of glycosylation whose impact is less
widely known is the mucin-like O-glycosylation of serine,
threonine and hydroxyproline residues, the latter being
unique to plants. However, recent efforts have addressed
the engineering of O-linked glycans [57]. It has been sug-
gested that O-glycan structures may function as adjuvants,
or may increase serum stability [51]. Tailored mammal-like
O-glycan structures could also improve the stability and
activity of proteins such as erythropoietin and secretory
IgA, giving plants a competitive edge for the production of
these compounds.
5.3 Vaccine bioencapsulation and delivery
Although plants have been shown to manufacture
biologically-active therapeutics in amounts sufficient for
oral administration to livestock, plant-derived antigens
require a formulation to protect them from the hostile
environment of the gastro-intestinal tract, without inter-
fering with the immunogenicity of the antigen. Depend-
ing on the plant species and the plant tissue in which
the subunit proteins are expressed, the plant matrix
could provide some protection against these harsh con-
ditions. Not only does this eliminate the need for costly
purification, but the provision of a durable matrix offers
a protective and stabilizing effect beyond harvest and
upon mucosal administration [58]. Any plant cell matrix
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thereby increasing exposure of a vaccine to immune
effector cells, but the protective effect can be further en-
hanced by incorporation of the vaccine proteins into
storage organelles [59]. The use of seeds is particularly
suitable to achieve bioencapsulation of recombinant pro-
teins in specialized storage organelles that are derived
from the endomembrane system and allow proteins to
accumulate within a protective matrix [52]. Clear benefits
have been demonstrated in seed-based production sys-
tems as recombinant proteins expressed in rice or pea
seeds were better protected from degradation than their
purified counterparts upon oral delivery [60,61]. Never-
theless, plant-based production could also negatively influ-
ence the immunogenicity of the antigen by influencing
antigen folding, glycosylation and/or by interaction with
the antigen, interfering with its capacity to target the mu-
cosa [46]. The latter could be one of the reasons why F4
fimbriae to which alfalfa crushed leaf biomass was added,
showed a decreased immune response in pigs in compari-
son with F4 without this plant material (Cox et al., unpub-
lished results).
5.4 Scale-up and speed
Scaling up production of recombinant proteins in trans-
genic or transplastomic plants is much easier and less
costly than similar scaling up in mammalian or micro-
bial cells for the simple reason that each plant could be
considered as a bioreactor and all that is required is
sowing a seed and providing light, water and fertilizer, as
opposed to an expensive upfront investment in infrastruc-
ture and bioreactor facilities for cell cultures and the for-
mulation of complex cell culture media. Therefore, scaling
up or down can be achieved quickly with no major invest-
ment. A single tobacco plant can produce over 150 000
seeds, allowing fast scale-up within a few months. To-
bacco biomass yields can reach up to 100 tons/ha in a sin-
gle field season [62]. If containment is necessary, a similar
or higher yield is achievable in greenhouses; and high level
accumulation of the desired protein at 1 g/kg fresh leaf
weight means that 100 kg of a protein can be produced in
a single hectare (Menassa et al., unpublished data). How-
ever, using stable transgenic/transplastomic lines implies a
lag time in producing a high expressing line and obtaining
seed. In the case of a catastrophic epidemic or pandemic,
much faster timelines are required. For this, transient pro-
duction in Nicotiana benthamiana is ideal with a timeline
from cloning of the genes to vaccine production of only a
few weeks [35]. As well, this system obviates the need for
production of transgenic plants, thus easing the regulatory
framework for scale up. In this system, wild type Nicoti-
ana benthamiana plants are grown in greenhouses and
infiltrated with Agrobacterium cultures containing the
expression construct required for recombinant proteinproduction. The infiltrated plants are harvested 4-10
days post-infiltration, and the protein is purified. Several
companies (Medicago Inc., Fraunhofer USA, Kentucky
BioProcessing LLC) have adopted this system for produc-
tion of influenza vaccines and monoclonal antibodies
[35,63,64]. The MagnICON® system developed by ICON
Genetics GmbH [65] allows the production and purifica-
tion of monoclonal antibodies at an expected yield of
250 mg/kg plant fresh weight [63], and Medicago Inc. was
able to produce 10 million doses of influenza vaccine
within one month in their 97 000 square foot facility in
North Carolina.
6. Examples of therapeutic proteins produced
in plants
6.1 Antibodies
It has been more than 25 years since the first IgG antibody
was expressed in plants. Since then, there have been nu-
merous publications in the scientific literature on the pro-
duction of antibodies in plants, such as those targeting
bacteria, cancer targets and highly pathogenic viruses such
as HIV and Ebola [66]. The current epidemic caused by
the Ebola virus in West Africa has brought attention to a
plant-produced antibody cocktail. This cocktail, called
ZMAPP, was recently shown to reverse advanced Ebola
disease in 100% of tested Rhesus macaques [67]. Six publi-
cations describe the production of five of 38 approved
therapeutic antibodies in plants (Table 1).
Therapeutic and prophylactic antibodies are required
in massive amounts and on a constant basis, and might
therefore be produced more economically by using trans-
genic plants rather than fermentation. In addition, neutral-
izing antibodies indicated as topical or oral microbicides
can also be delivered in plant material such as seeds, as
demonstrated by the administration of peas containing
single-chain antibodies with high sporozoite-neutralizing
activity against the coccidiosis parasite, Eimeria tenella,
for the prevention of gastrointestinal infections in chick-
ens [60]. In another, more recent study the protection of
weaned piglets against enterotoxigenic E. coli infection
was achieved by the oral administration of seeds produ-
cing IgA [72].
Whereas simple proteins such as single chain antibody
fragments tend to be easily expressed in bacteria, complex
glycoproteins such as monoclonal antibodies usually re-
quire eukaryotic production systems. Full size antibodies
tend to be expressed well in plants because the secretory
pathway in plant cells contains an extensive molecular
chaperone system. Plants are particularly beneficial for the
production of secretory IgA molecules because they can
produce all four of the polypeptide components and as-
semble a fully functional molecule [73]. In contrast, three
of the protein components are produced by plasma cells
in mammals, but the fourth is produced by epithelial cells,
Table 1 PubMed listings for therapeutic antibodies
produced in plants
Antibody
(generic name)
Antibody
(commercial name)
Plant
species
Reference
Cetuximab Erbitux Zea mays [68]
Nimotuzumab BIOMAb EGFR, TheraCIM,
Theraloc, CIMAher
Nicotiana
tabacum
[69]
Palivizumab Synagis Nicotiana
benthamiana
[70]
Rituximab Rituxan, Mabthera Lemna minor [56]
Trastuzumab Herceptin Nicotiana
benthamiana
[71]
ZMAPP - Nicotiana
benthamiana
[67]
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ment. Secretory IgA assembly can also be achieved in
CHO cells carrying the four different transgenes, but the
efficiency of assembly is low [74]. Therefore, plants offer a
valuable and superior large-scale production system for
this preferred format of mucosal antibodies.
6.2 Antigens: VLPs
Viral diseases are probably the most important culprit
for the severe economic losses in livestock production
worldwide. Although antibiotics are not used to treat or
prevent viral infection outbreaks, pathogenic viruses often
predispose infected animals for secondary bacterial infec-
tions, which do require antibiotic treatment. Thus, pre-
ventive vaccinations to control primary viral infections
help to reduce the need for antibiotics application in live-
stock production.
Virus-like particles (VLPs) are defined as multisubunit
protein structures with self-assembling competence that
show an identical or highly similar overall structure to
the corresponding native viruses [75]. Studies document
a high immunogenic capacity of VLPs due to their dis-
play of multiple repeated antigenic motifs, which trigger
B cell activation and elicit higher antibody titers com-
pared to monomeric antigens. Strong humoral immune
responses could be induced by VLPs without adjuvants,
while avoiding stimulation of inflammatory T cell re-
sponses [76]. Many different VLPs (more than 100) origin-
ating from phages and plant, insect, and vertebrate viruses
have been described and summarized in an excellent
review [75], including examples of the preparative and
large-scale manufacturing of VLPs in bacteria, yeast cells,
insect cells and mammalian cells.
Mason et al. first demonstrated that the expression of
human hepatitis B virus structural proteins in plants
results in enveloped VLPs that “bud-out” as spherical
particles of 22 nm in diameter off the intracellular mem-
branes [77]. The further engineering of enveloped hepa-
titis B virus VLPs into nanoparticles allowed the displayof large foreign antigens or the development of bivalent
vaccines [78]. Simultaneous transient expression of four
distinct structural proteins of Bluetongue virus (BTV)
led to assembly of heteromultimeric VLPs able to elicit a
strong antibody response in sheep, which provided protect-
ive immunity against BTV challenge [79]. Another example
of VLPs produced in plants with improved transient
expression is Norwalk virus-derived non-enveloped VLPs
[80]. Lettuce containing low levels of secondary metabo-
lites has been used to develop a robust plant virus-based
production platform for VLPs derived from the Norwalk
virus capsid and combined with a scalable processing
method [81].
The concept of producing VLPs in plants is generally
connected to the idea of edible vaccines [75]. However,
there are several hurdles to resolve before this concept
could be implemented, despite all of its obvious benefits.
Quality control issues and precise formulation of vaccine
products, as well as documented control by the relevant
regulatory bodies would preclude easy on-site produc-
tion in food/feed plant organs. The administration of
such vaccines has to be regulated to avoid insufficient
antigen application or, vice versa, to avoid the develop-
ment of immune tolerance. Even orally administered VLP-
type vaccines will have to be at least processed, enriched,
formulated and applied under supervision, to ensure re-
producible results [29].
Both the most recent and the most successful application
of the plant-based VLP concept has been by Medicago Inc.
(for review see [35]). A proprietary, plant-based transient
expression system has been developed to produce vaccines
made of budded influenza hemagglutinin particles [82].
The developed platform allowed the vaccine to be pro-
duced within one month of the disclosure of hemagglutinin
sequences, from identified strains as H1N1 [82]. Because
many influenza types (i.e. H5N1, H1N1) are zoonotic dis-
eases, vaccination with plant-based VLPs has to be further
developed especially in terms of lowering down-stream pro-
cessing costs to fit into the economic constraints associated
with a veterinary vaccine. An excellent comparative sum-
mary of different plant-based vaccines including expression
levels, immunogenicity, VLP strategies and anticipated cost
is given in a review by Scotti and Rybicki [83]. The authors
conclude that proof of efficacy was demonstrated for sev-
eral plant-based VLP vaccines and plant-based expression
systems could do as well as conventional production sys-
tems based on fermentation. They claim a rather optimis-
tic future of plant-based VLPs, if real costs are in the
predicted range.
6.3 Subunit vaccines
The concept of using plants as expression hosts for vet-
erinary subunit vaccines has been studied extensively
within the past two decades. However, only a few studies
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in farm animals. This section summarizes examples show-
ing immunization data with host species.
6.3.1 Poultry
In 2006 Dow Agro Sciences obtained USDA approval
for a plant cell culture-based vaccine for poultry against
Newcastle disease virus [84]. This vaccine was composed
of recombinant hemagglutinin-neuraminidase protein
expressed in transgenic tobacco suspension cells and
formulated as an injectable vaccine. Other studies on
Newcastle disease virus include expression of full-size
glycoproteins in transgenic potato and tobacco leaves,
maize and rice seeds (reviewed in [85]). The antigens
were shown to be immunogenic and protective in chick-
ens after oral delivery.
An edible potato-based vaccine has been developed
against chicken infectious bronchitis virus (IBV) [86].
Sliced tubers expressing viral S1 glycoprotein were admin-
istered in three doses over two weeks; chickens were chal-
lenged with IBV one week after the last administration.
Orally immunized chickens developed a virus-specific
antibody response and were protected against IBV. An-
other research group succeeded in vaccinating chickens
against infectious bursal disease virus (IBDV) with plant-
made VP2 protein. Chickens orally immunized with Ara-
bidopsis crude leaf extracts or transgenic rice seeds were
protected to a similar level achieved with a commercial in-
jectable vaccine [87]. Recently, the VP2 antigen was pro-
duced transiently in Nicotiana benthamiana and induced
neutralizing antibodies in immunized chickens [88].
6.3.2 Swine
The use of maize seeds as an edible delivery vehicle
against porcine Transmissible gastroenteritis coronavirus
(TGEV) has been extensively studied. The envelope spike
protein was used as an antigen to raise neutralizing anti-
bodies and the efficacy of this plant-made vaccine has been
presented in experiments with piglets [89]. In addition, it
was found that the antigen was stable during storage in
various conditions and authors were able to concentrate
the antigen using milling techniques.
Enterotoxigenic E. coli (ETEC) causing post-weaning
diarrhea in piglets has been a target for a plant-made
vaccine. The major subunit protein of ETEC F4 fimbriae
has been expressed in the leaves of tobacco [90], alfalfa
[46] and in seeds of barley [91]. This subunit vaccine was
shown to be immunogenic and partially protective after
oral delivery to weaned piglets [46].
Capsid protein VP1 antigenic epitope of the of Foot-
and-mouth disease virus (FMDV) was used to substitute
a part of Bamboo mosaic virus coat protein, resulting
in display of the epitope on virions that retained their
infectivity and could be propagated in plants [92]. Itwas demonstrated that immunization with the extracted
chimeric virions by intramuscular injection could fully
protect pigs against FMDV challenge by effectively indu-
cing humoral and cell-mediated immune responses.
6.3.3 Cattle
Transgenic peanut plants expressing bovine Rinderpest
virus hemaglutinin raised immune responses in cattle
[93]. This oral vaccine was able to raise virus-specific anti-
bodies which also neutralized the virus in vitro. Immuno-
genicity of a Tobacco mosaic virus (TMV)-based vaccine
against bovine herpes virus (BHV) was studied in cattle
[94]. Immunogenic glycoprotein D was produced as a by-
product in TMV-inoculated tobacco plants, and the crude
plant extract emulsified in oil and subsequently injected
into cattle was able to raise specific humoral and cellular
immune responses. Most importantly, cattle were pro-
tected against BHV to similar levels as those vaccinated
with the commercial vaccine.
A plant-made subunit vaccine against Bovine viral diar-
rhea virus (BVDV) has been developed in Argentina. The
structural protein E2 of BVDV was expressed in transgenic
alfalfa as a fusion to a peptide for targeting the product to
antigen-presenting cells [95]. Partially purified antigen was
administered intramuscularly to calves and protected them
against BVDV challenge.
6.4 Toxic proteins
Although the efficacy of treatments with classical antibi-
otics is declining due to the widespread development of
antibiotic resistance among major pathogenic bacteria,
there are very little alternatives for fighting infections.
One novel therapeutic option could be the use of phage
lysins - enzymes that target and hydrolyze bacterial cell
walls, efficiently killing a large array of bacteria [96]. How-
ever, due to the toxic nature of these proteins, their pro-
duction in bacteria cannot be achieved, limiting the
availability for testing or manufacture. The lack of the spe-
cific, bacterial-type cell wall structures targeted by lysins
makes plants an alternative platform for production of
therapeutic proteins which are highly toxic to bacteria. In
a promising report [97], Oey et al. showed that by target-
ing the genes encoding the lysozyme Cpl-1 and the ami-
dase Pal to the tobacco plastome, functional lysins could
be synthesized and accumulated at high levels in chloro-
plasts. Several reports described successful transplastomic
as well as transient expression-mediated production of
short anti-microbial peptides, analogs of secreted defen-
sins, which can be used for control of bacterial, viral and
fungal infections [98-100]. Hence, plants represent a valu-
able production system for anti-microbial toxic proteins,
offering cost-effective solution to obtain large quantities
of proteinaceous antibiotics that could be administered
through feed.
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The use of vaccines and prophylactics for the control of
infectious diseases in the livestock industry will grow as
antibiotics applications diminish. Plants as bioreactors
comprise a valuable option for production of recombinant
protein therapeutics for animal health. In recent years nu-
merous studies demonstrated the feasibility and advantages
of plant-based production platforms for various proteins
with therapeutic use, including complex antibodies, sub-
unit vaccines and immunogenic virus-like particles. Plant-
made therapeutic products are currently on the cusp of
widely entering biotechnology markets. Interaction and
concerted actions of the plant biotechnology sector with
veterinarians and regulatory authorities will facilitate devel-
opment of novel approaches to sustainable, antibiotic-free
livestock agriculture.
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